Loading stock data…
AMPH
$18.87-0.13 (-0.68%)
Market OpenUpdated 2:41 PM EDT
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Amphastar Pharmaceuticals, Inc. in the Healthcare sector is trading at $18.87. The stock is currently near its 52-week low of $17.03, remaining 24.8% below its 200-day moving average. Technical signals show neutral RSI of 37 and bearish MACD signal, explaining why AMPH maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 37) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$18.87
Potential Upside
106.9%
Whystock Fair Value$39.05
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus6 analysts
Hold
Mean target$25.17+33.4%
Range$21.00 – $30.00
Fundamentals
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$935.68M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
10.35
Beta
Defensive asset. Lower volatility than the S&P 500.
0.91
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
17.08%
Volume
Today's trading volume
691,924
Recent News
Earnings Miss: Amphastar Pharmaceuticals, Inc. Missed EPS By 75% And Analysts Are Revising Their Forecasts
There's been a notable change in appetite for Amphastar Pharmaceuticals, Inc. ( NASDAQ:AMPH ) shares in the week since...
Amphastar Pharmaceuticals (AMPH) Is Up 9.4% After Profit Falls Despite New Drug Launches And Licensing Deals
Amphastar Pharmaceuticals, Inc. reported past first-quarter 2026 results with net revenues of US$171.17 million, but net income dropped to US$6.42 million and diluted EPS fell to US$0.14 amid higher costs. Despite launching its new Ipratropium Bromide HFA inhalation product and entering a synthetic corticotropin license agreement, Amphastar’s sharply lower profitability and missed earnings expectations raised concerns about cost pressures on the business. Next, we’ll examine how this profit...
Amphastar Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
Moby summary of Amphastar Pharmaceuticals, Inc.'s Q1 2026 earnings call
Amphastar (AMPH) Q1 2026 Earnings Transcript
Dan Dischner: Thank you, Paul. Good afternoon, everyone, and thank you for joining Amphastar Pharmaceuticals, Inc.'s first quarter 2026 earnings call. Before we begin, I would like to recognize the continued dedication of our employees across Amphastar Pharmaceuticals, Inc. Their commitment to ensuring reliable access to essential medicines remains central to who we are and how we operate.
Compared to Estimates, Amphastar (AMPH) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.